Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus nab-paclitaxel and S-1 for conversion therapy in unresectable advanced or metastatic gastric cancer
ChiCTR2200062653Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tislelizumab, paclitaxel and tegafur in gastric cancer (GC) (2 cohorts), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: R0 resection rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
tislelizumabpaclitaxeltegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2200062653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062653.